Warning letter
Pulmoniare Service, Inc.: warning letter of Feb 22, 2002
FDA warning letter UCM146789 · New Orleans District Office
Key facts
| Reference number | UCM146789 |
|---|---|
| Company | Pulmoniare Service, Inc. |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 22, 2002 |
| Posted date | Feb 22, 2002 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| Country | 3 |
| Inspection city | Chattanooga |
| Inspection ZIP | 37403-2600 |
| Inspection start date | Jan 9, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: